Objective:

To characterize the longitudinal plasma proteomic changes in psoriasis patients treated with secukinumab and identify potential biomarkers for disease monitoring and treatment response, emphasizing their clinical significance.

Key Findings:

• Baseline plasma profiles distinguished psoriasis patients from healthy controls, with CXCL1, CXCL5, CCL20, and HGF showing significant alterations.
• Post-treatment, there was a coordinated reduction in inflammatory mediators such as CCL20, IL-17C, IL-6, and OSM, with statistical significance noted.
• IL-17C levels at baseline correlated positively with disease severity, indicating its potential as a therapeutic response biomarker.

Interpretation:

The study provides molecular evidence of systemic immunomodulatory effects following IL-17A blockade in psoriasis, highlighting candidate biomarkers for monitoring treatment response and their potential implications for clinical practice.

Limitations:

• Small sample size of 10 patients, necessitating validation in larger cohorts and consideration of multi-center studies.
• Single-center study may limit generalizability of findings; future research should aim for broader demographic representation.

Conclusion:

This research offers insights into the plasma proteomic landscape in psoriasis patients undergoing secukinumab therapy, suggesting potential biomarkers for clinical monitoring and their relevance in the context of existing literature.